ClinicalTrials.gg
RecruitingNCT07708727Updated Nov 10, 2026

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

A Phase 2/3 interventional study of GS-3242 Tablet and GS-3242 Injection in HIV-1-infection, sponsored by Gilead Sciences. Recruiting at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 10, 2026First sites in Germany and Spain12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B.

The goal of Phase 2, Part A is to assess the effectiveness of study drugs GS-3242 plus Lenacapavir (LEN) versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in people with HIV-1 (PWH) who are new to treatment. This will be done in Treatment Groups 1, 2 and 3 at Week 35.

The goal of Phase 2, Part B is to compare the effectiveness of study drugs, GS-3242 and LEN versus B/F/TAF in Groups 4 and 3 at Week 26.

The goal of Phase 3 is to assess the long-term effectiveness of study drug GS-3242 and LEN versus B/F/TAF, at Week 52.

The primary objectives of this study are:

Phase 2, Part A: To evaluate the efficacy of intramuscular (IM) GS-3242 plus IM LEN versus B/F/TAF in treatment-naive people with HIV-1 (PWH) in Treatment Groups 1, 2, and 3 at Week 35. Phase 2, Part B: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH in Treatment Groups 4 and 3 at Week 26.

Phase 3: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH at Week 52.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • -1 ribonucleic acid (RNA) ≥ 500 copies/mL at screening.
  • Antiretroviral (ARV) treatment-naive, except for prior use of oral daily pre-exposure prophylaxis (PrEP) or postexposure prophylaxis (PEP) up to 1 month prior to screening.

Key Exclusion Criteria:

  • Prior usage of, or exposure to LEN or GS-3242
  • Prior use of any long-acting parenteral ARV therapy (ART) medications such as monoclonal antibodies or broadly neutralizing antibodies targeting HIV-1, injectable cabotegravir (including oral cabotegravir lead-in), or injectable rilpivirine.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Phase 2: Part A: Group 1 of GS-3242 + LEN

    Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by intramuscular (IM) injections of GS-3242 and LEN for at least 52 weeks.

    Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Phase 2: Part A: Group 2 of GS-3242 + LEN

    Participants will be randomized oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 (at a different dose than Group 1) and LEN for at least 52 weeks.

    Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Phase 2: Part A: Group 3 of B/F/TAF

    Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 52 weeks.

    Drug: B/F/TAF

  • Experimental
    Phase 2: Part B: Group 4 of GS-3242 + LEN

    Participants will be enrolled (non-randomized) to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed IM injections of GS-3242 and LEN (at different doses than Group 1 and 2) for at least 52 weeks.

    Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Phase 3: Group 1 of GS-3242 + LEN

    Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 and LEN for at least 104 weeks.

    Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection

  • Experimental
    Phase 3: Group 2 of B/F/TAF

    Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 104 weeks.

    Drug: B/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm

    Time frame: Week 35

  2. Phase 2: Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 26

  3. Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 52

Secondary outcomes

  1. Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 12

  2. Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm

    Time frame: Week 52

  3. Phase 2: Parts A and B: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 12

    Time frame: Baseline, Week 12

  4. Phase 2: Part A: Change From Baseline in CD4 Cell Count at Week 35

    Time frame: Baseline, Week 35

  5. Phase 2: Parts A and B: Change From Baseline in CD4 Cell Count at Week 52

    Time frame: Baseline, Week 52

  6. Phase 2: Part B: Change From Baseline in CD4 Cell Count at Week 26

    Time frame: Baseline, Week 26

  7. Phase 2: Parts A and B: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 12

    Time frame: From first dose date up to Week 12

  8. Phase 2: Part A: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 35

    Time frame: Week 35

  9. Phase 2: Part B: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 26

    Time frame: From first dose date up to Week 26

  10. Phase 2: Parts A and B and Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52

    Time frame: From first dose date up to Week 52

  11. Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 18

    Time frame: Week 18

  12. Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 35

    Time frame: Week 35

  13. Phase 2: Part A and Part B: Trough Concentrations of GS-3242 and LEN at Week 52

    Time frame: Week 52

  14. Phase 2: Part B: Trough Concentrations of GS-3242 and LEN at Week 26

    Time frame: Week 26

  15. Phase 3: Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 104 as determined by the US FDA snapshot algorithm

    Time frame: Week 104

  16. Phase 3: Change From Baseline in CD4 Cell Count at Week 52

    Time frame: Baseline, Week 52

  17. Phase 3: Change From Baseline in CD4 Cell Count at Week 104

    Time frame: Baseline, Week 104

  18. Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52

    Time frame: From first dose up to Week 52

  19. Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 104

    Time frame: From first dose up to Week 104

07

Study locations

19 of 21 sites recruiting
  • Lundquist Inst Biomedical Innovation Harbor-UCLA
    Torrance, California 90502, United States
    Recruiting
  • Yale University; School of Medicine; AIDS Program
    New Haven, Connecticut 06510, United States
    Recruiting
  • Midway Immunology and Research Center
    Ft. Pierce, Florida 34982, United States
    Recruiting
  • Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Orlando Immunology Center, PA
    Orlando, Florida 32803, United States
    Recruiting
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Emory University Hospital Midtown Infectious Disease Clinic
    Atlanta, Georgia 30308, United States
    Recruiting
  • Metro Infectious Disease Consultants, P.L.L.C
    Decatur, Georgia 30033, United States
    Recruiting
  • KC care Health Center
    Kansas City, Missouri 64111, United States
    Recruiting
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
    Recruiting
  • St Hope Foundation, Inc,
    Bellaire, Texas 77401, United States
    Recruiting
  • Prism Health North Texas
    Dallas, Texas 75208, United States
    Recruiting
  • North Texas Infectious Diseases Consultants, PA
    Dallas, Texas 75246, United States
    Recruiting
  • Texas Centers for Infectious Disease Associates
    Fort Worth, Texas 76109, United States
    Recruiting
  • MultiCare Health System - Deaconess Medical Office Building 2
    Spokane, Washington 99202, United States
    Recruiting
  • McGill University Health Centre
    Decarie Montreal, H4A 3J1, Canada
    Recruiting
  • CHU de Québec-Université Laval
    Québec, G1V 4G2, Canada
    Recruiting
  • ICH Study Center GmbH & Co. KG
    Hamburg, 22083, Germany
    Not yet recruiting
  • Proyecto ACTU
    Rio Piedras, PR 00925, Puerto Rico
    Recruiting
  • HOPE Clinical Research
    San Juan, PR 00909, Puerto Rico
    Recruiting
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Oct 2030, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 16, 2026
StartActual
Jul 29, 2026
Primary completionEst.
Oct 2030
CompletionEst.
Apr 2033
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 2 sites removed — first sites in Germany and Spain
Show 12 added (7 United States, 2 Canada, 1 Puerto Rico, 1 Germany, 1 Spain)
  • Lundquist Inst Biomedical Innovation Harbor-UCLA · Torrance, United States
  • Yale University; School of Medicine; AIDS Program · New Haven, United States
  • Orlando Immunology Center, PA · Orlando, United States
  • Emory University Hospital Midtown Infectious Disease Clinic · Atlanta, United States
  • McGill University Health Centre · Decarie Montreal, Canada
  • CHU de Québec-Université Laval · Québec, Canada
  • Proyecto ACTU · Rio Piedras, Puerto Rico
  • Floridian Clinical Research, LLC · Miami Lakes, United States
  • Saint Michael's Medical Center · Newark, United States
  • MultiCare Health System - Deaconess Medical Office Building 2 · Spokane, United States
  • ICH Study Center GmbH & Co. KG · Hamburg, Germany
  • Hospital Universitario Virgen de las Nieves · Granada, Spain
Show 2 removed
  • Orlando Immunology Center, PA · Florida City, United States
  • McGill University Health Centre · Montreal, Canada
across 2 updates, Oct 13, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    5 sites added — first sites in Germany and Spain
    Show 5 added (3 United States, 1 Germany, 1 Spain)
    • Floridian Clinical Research, LLC · Miami Lakes, United States
    • Saint Michael's Medical Center · Newark, United States
    • MultiCare Health System - Deaconess Medical Office Building 2 · Spokane, United States
    • ICH Study Center GmbH & Co. KG · Hamburg, Germany
    • Hospital Universitario Virgen de las Nieves · Granada, Spain
    + 1 other change: verification date
  2. Oct 13, 2026
    7 sites added, 2 sites removed
    Show 7 added (4 United States, 2 Canada, 1 Puerto Rico)
    • Lundquist Inst Biomedical Innovation Harbor-UCLA · Torrance, United States
    • Yale University; School of Medicine; AIDS Program · New Haven, United States
    • Orlando Immunology Center, PA · Orlando, United States
    • Emory University Hospital Midtown Infectious Disease Clinic · Atlanta, United States
    • McGill University Health Centre · Decarie Montreal, Canada
    • CHU de Québec-Université Laval · Québec, Canada
    • Proyecto ACTU · Rio Piedras, Puerto Rico
    Show 2 removed
    • Orlando Immunology Center, PA · Florida City, United States
    • McGill University Health Centre · Montreal, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07708727
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 29, 2026
Primary completion
Oct 2030 (estimated)
Completion
Apr 2033 (estimated)
Last update
Nov 10, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
leadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GS-3242 · Lenacapavir · Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion